Picard Medical, Inc. announced that Dr. Andre Simon, Vice President of Clinical Affairs, will deliver three scientific and educational presentations at the Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston from March 2-4, 2026. Presentations will cover the current SynCardia Total Artificial Heart (STAH) and the next-generation fully implantable Emperor system. Early laboratory and preclinical data for the Emperor system demonstrate preservation of STAH's proven physiologic performance, with a design aimed at eliminating transdermal pneumatic drivelines for improved mobility, quality of life, and patient independence. Updated registry analyses for the SynCardia Total Artificial Heart highlight outcomes beyond survival, including stabilization, organ recovery, functional improvement, and preservation of transplant eligibility. Key findings for STAH include sustained clinical success in critically ill patients, improved outcomes with earlier implantation, strong recovery potential for initially transplant-ineligible patients, and significant quality of life improvements post-recovery. Dr. Simon will also discuss the future evolution of total artificial heart therapy, focusing on clinical priorities like earlier intervention, organ recovery, improved patient selection, and the shift towards durable long-term support.